Abstract
Chronic myelogenous leukemia (CML) is the most common and best studied of the chronic myeloproliferative disorders, resulting from a characteristic Philadelphia chromosomal abnormality, t(9;22)(q34q11). The molecular consequence of this chromosomal translocation is production of a hybrid BCR-ABL (breakpoint cluster region–Abelson leukemia virus) fusion protein product (p210) with tyrosine kinase activity and transforming properties. Morphologic, cytogenetic, and molecular studies are essential in the diagnosis and monitoring of patients with CML. Newer chemotherapeutic agents and hematopoietic stem cell transplantation have substantially improved the prognosis for patients with CML.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
